DeepMed Research

Zongertinib

Generic Name: Zongertinib

Clinical Trials

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Phase 2

Recruiting

Conditions: Solid Tumours

Interventions: Drug: Zongertinib

First Posted Date: 2024-09-03

Last Posted Date: 2025-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT06581432

Locations: 🇫🇷
CTR Georges-François Leclerc, Dijon, France
🇧🇪
Edegem - UNIV UZ Antwerpen, Edegem, Belgium
🇺🇸
Alaska Oncology and Hematology, LLC, Anchorage, Alaska, United States

and more 61 locations

A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Zongertinib
Drug: Dabigatran-etexilate
Drug: Rosuvastatin
Drug: Metformin hydrochloride
Drug: Furosemide

First Posted Date: 2024-07-17

Last Posted Date: 2025-03-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT06504862

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: zongertinib
Drug: midazolam
Drug: omeprazole
Drug: repaglinide

First Posted Date: 2024-07-10

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT06494761

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Zongertinib

First Posted Date: 2024-04-11

Last Posted Date: 2024-07-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT06360081

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1

Recruiting

Conditions: Metastatic Breast Cancer
Metastatic Gastric Adenocarcinoma
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Zongertinib
Drug: Trastuzumab emtansine
Drug: Trastuzumab deruxtecan
Drug: Trastuzumab
Drug: Capecitabine

First Posted Date: 2024-03-21

Last Posted Date: 2025-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 582

Registration Number: NCT06324357

Locations: 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸
Sharp Memorial Hospital, San Diego, California, United States

and more 47 locations

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3

Recruiting

Conditions: Lung Cancer, Non-squamous, Non-small Cell

Interventions: Drug: pembrolizumab
Drug: zongertinib
Drug: cisplatin
Drug: carboplatin
Drug: pemetrexed

First Posted Date: 2023-11-30

Last Posted Date: 2025-05-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 270

Registration Number: NCT06151574

Locations: 🇫🇷
HOP Civil, Strasbourg, France
🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸
Mohtaseb Cancer Center and Blood Disorders, LLC, Bullhead City, Arizona, United States

and more 164 locations

A Study in Healthy Men to Test How BI 1810631 is Taken up in the Body When Taken With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1810631

First Posted Date: 2023-10-10

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT06075277

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of BI 1810631 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1810631
Drug: Carbamazepine

First Posted Date: 2023-09-08

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT06028464

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1810631 (C-14) formulation 1
Drug: BI 1810631
Drug: BI 1810631 (C-14) formulation 2

First Posted Date: 2023-05-30

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT05879991

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1810631 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1810631
Drug: Itraconazole

First Posted Date: 2023-04-27

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT05833139

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy